The online version of this article (doi:10.1186/1477-7819-10-118) contains supplementary material, which is available to authorized users.
The authors indicated no potential conflicts of interest.
Conception and design: KJ, SV, PT. Administrative support: KJ, SV, AK, AB. Provision of study materials or patients: KJ, SV, AK. Collection and assembly of data: SV, AK. Data analysis and interpretation: KJ, AK, PT. Manuscript writing: KJ, SV, AK. Review of manuscript: DF, PT, RB, EY. Final approval of manuscript: KJ, SV, AK, AB, DF, PT, RB, EY. All authors read and approved the final manuscript.
This project was supported by the Health Quality Council of Alberta (HQCA). Partly presented at the annual CARO meeting 2011, Winnipeg, Manitoba, Canada.
To analyze the characteristics and outcomes of women with breast cancer in the Northern Alberta Health Region (NAHR) who declined recommended primary standard treatments.
A chart review was performed of breast cancer patients who refused recommended treatments during the period 1980 to 2006. A matched pair analysis was performed to compare the survival data between those who refused or received standard treatments.
A total of 185 (1.2%) patients refused standard treatment. Eighty-seven (47%) were below the age of 75 at diagnosis. The majority of those who refused standard treatments were married (50.6%), 50 years or older (60.9%), and from the urban area (65.5%). The 5-year overall survival rates were 43.2% (95% CI: 32.0 to 54.4%) for those who refused standard treatments and 81.9% (95% CI: 76.9 to 86.9%) for those who received them. The corresponding values for the disease-specific survival were 46.2% (95% CI: 34.9 to 57.6%) vs. 84.7% (95% CI: 80.0 to 89.4%).
Women who declined primary standard treatment had significantly worse survival than those who received standard treatments. There is no evidence to support using Complementary and Alternative Medicine (CAM) as primary cancer treatment.
National Cancer Institute of Canada: Canadian cancer statistics 2011, Toronto, ON, Canada 2011.
Kuerer HM, Newman LA, Smith TL: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999, 17 (2): 460-469. PubMed
Huchcroft SA, Snodgrass T: Cancer patients who refuse treatment. Cancer Causes and Control. 1993, 4: 179-292. PubMed
Shumay DM, Maskarinec G, Kakai H, Gotay CC: Why some cancer patients choose complementary and alternative medicine instead of conventional treatment. J Fam Pract. 2001, 50: 1067- PubMed
- Outcome analysis of breast cancer patients who declined evidence-based treatment
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II